Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

There is an urgent need for novel targeted therapy for osteosarcoma (OS). Molecular targeted therapy has yielded stunning response rates of >90% for specific targets such as NTRK gene fusions. In contrast, the mainstay of therapy for osteosarcoma has remained the same for more than 30 years and few targeted agents have successfully translated to the clinic for OS patients.

The challenge to develop targeted therapies for osteosarcoma is that the tumor has different driver mutations in different patients. However, 12-39% of tumors share a common amplification in a gene called MYC. In this project, Dr. Grohar and colleagues will consider this subset of osteosarcoma as a distinct entity. They are characterizing the role of MYC in the pathogenesis of osteosarcoma and determining how MYC makes osteosarcoma aggressive. Ultimately, they will identify compounds that will serve as clinical candidates for MYC-driven osteosarcoma. They will then determine if they are best translated to the clinic as single agents, in combination with chemotherapy, or as metastasis-targeted therapy.

Dr. Grohar has assembled a team with the necessary expertise. Chand Khanna is a disease expert in osteosarcoma, the Grohar lab has expertise in drug development for bone sarcomas, the Neamati and O'Keefe labs are experts in drug discovery/chemical biology/natural products. Filemon Dela Cruz is an expert in preclinical drug modeling, Ted Laetsch and Rashmi Chugh are experts in sarcoma clinical trial design, and Ethos (led by Chand Khanna) and Vuja De (led by David Warshawsky) are companies that will aid in the development of these compounds for the clinic. Together they will identify compounds that are specific and effective for MYC amplified osteosarcoma. This grant was awarded at Children's Hospital of Philadelphia and transferred to the University of Michigan.

To make a significant impact for kids fighting osteosarcoma, five funding partners have banded together with St. Baldrick’s to support this grant – The Fight Osteosarcoma Together (FOT) Super Grant supported by Battle Osteosarcoma, CureSearch for Children’s Cancer, Michael and April Egge, The Osteosarcoma Collaborative, and the Zach Sobiech Osteosarcoma Fund of Children’s Cancer Research Fund.

Though most children with cancer are able to be cured, some children are more likely to be cured than others, even with the best available treatments. Childhood cancer treatment is a long and difficult process for children and their families, and most families need support from those around them including community support and resources. Adults with cancer living in disadvantaged communities are much more likely to die from their cancer, though much less is known about how the characteristics of the community impact outcomes for children with cancer. Dr. Hoppmann uses a large national cancer database, coupled with measures of social determinants of health (measures of poverty, healthcare access, educational attainment, social and physical environment) to determine how these community vulnerabilities impact children with cancer. Results will help ensure gains made in pediatric cancer are shared equitably among all children, including those from disadvantaged areas.

Acute Lymphoblastic Leukemia (ALL) are aggressive cancers of B- and T- immune cells. ALL is most common in children but also affects adolescents and young adults. 90% of childhood ALL is curable. However, ~10% of children and ~30% of adolescents and young adults with ALL are not cured. To combat hard-to-treat ALL, Dr. Swaminathan will harness the body’s natural anti-cancer defense mechanism: a type of immune cell called a natural killer (NK) cell. He will also find defective NK cells in children with ALL. Those with fewer defective NK cells tend to survive longer and spend more of their lives free from disease compared to patients with high levels of abnormal NK cells. These findings will inform the development of NK cells as affordable therapies to cure pediatric ALL.

Leukemia, a cancer of the blood and bone marrow, is the most common cancer in kids. Over the last 60 years, great strides have been made in treating children with leukemia, and today, most leukemias are curable. However, certain leukemias are difficult to treat and have a poor prognosis. In order to better treat cancers, researchers seek to better understand the pathways by which cancer cells develop in order to identify medicines that target proteins in these pathways. Dr. Aumann and colleagues study the fusion protein CALM-AF10 which is found in some leukemias, and found that these leukemias have increased expression of a protein called SIX1. Dr. Aumann is studying how the SIX1 protein makes blood cells turn into leukemia cells, and is using two small molecule inhibitors in combination with other chemotherapy as potential new treatments for this and other leukemias. The hope is that the these studies will clarify the role of SIX1 in CALM-AF10 and other leukemias.